by The global cancer immunotherapy market size is forecasted to reach from US$ 85 billion in 2021 to US$ 277.1 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 12.6% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.
The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.
The cancer immunotherapy market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1394
The rising prevalence of various cancer such as colorectal cancer, bowel cancer, breast cancer, and lungs cancer among the global population and rising adoption of the immunotherapy to treat cancer is boosting the growth of the global cancer immunotherapy market. The rising awareness regarding the advantages of the cancer immunotherapy over the conventional chemotherapies is further driving the demand for the cancer immunotherapy among the cancer patients. The rising disposable income, availability of advanced healthcare facilities, and rising consumer expenditure on healthcare is positively impacting the growth of the global cancer immunotherapy market. Cancer Immunotherapy has less side effects and have long term treatment affects, which boosts the demand for the cancer immunotherapy across the globe.
Scope of the Cancer Immunotherapy Market Report
| Report Highlights | Details |
| Market Size | USD 277.1 Billion by 2030 |
| Growth Rate | CAGR of 12.6% From 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Technology, Cancer Type, End User, Region |
Competitive Intelligence
The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.
Some of the prominent players in the global cancer immunotherapy market are listed as below:
- Amgen, Inc.
- Astrazeneca, PLC
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lily And Company
- F. Hoffmann-La Roche, Ltd
- Pfizer, Inc.
- Johnson & Johnson
- Merck KGAA
- Novartis AG
Market Dynamics
Driver
Rising awareness regarding the cancer immunotherapy
The technological advancements in the biologics has encouraged the development of the cancer immunotherapy. Moreover, certain inconveniences associated with the conventional chemotherapy such as reoccurrence of cancer, organ failure, and high costs have compelled the patients to opt for improved cancer treatment solutions. Hence, the less side-effects and improved treatment offered by the cancer immunotherapy is expected to drive the market growth.
Restraints
High cost of the therapy
The high costs associated with the acquisition of the cancer immunotherapy may restrict the low and middle income patients to afford the cancer immunotherapy and hence may hinder the market growth in the forthcoming years.
Opportunities
The rising adoption of healthcare insurance
The high healthcare costs and rising burden of diseases across the globe has compelled the population to buy a healthcare insurance. The medical and financial assistance provided by the healthcare insurances is expected to drive the adoption of the cancer immunotherapy among the cancer patients across the globe.
Challenges
Lack of awareness among the population
The major challenge for the market players is to spread the awareness regarding the benefits of getting the cancer immunotherapy. However, the lack of awareness in the developing and the underdeveloped regions regarding the availability of cancer immunotherapy is restricting the growth of the market.
Regional Snapshot
North America dominated the global cancer immunotherapy market in 2020. This is primarily due to the increased prevalence of cancer in the region. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The lungs cancer, colorectal cancer, breast cancer, and prostate cancer are the top four cancers that prevails in the US. Further, the increased disposable income, increased awareness regarding the benefits of the cancer immunotherapy among the population, and presence of strong and advanced healthcare infrastructure in the region is augmenting the market growth.
Europe is estimated to be the fastest-growing market during the forecast period. The high disposable income, rising healthcare expenditure, and rising awareness regarding the cancer immunotherapy is expected to drive the market growth in this region. Further, rising cancer cases and cancer deaths in the region is further fueling the market growth.According to the European Commission, around 2.7 million new cancer cases and around 1.3 million cancer deaths were reported in 2020. The geriatric population of aged 65 years or above were the most affected by cancer in Europe. Breast cancer has been recorded as the most diagnosed cancers across the European countries in 2020.
Report Highlights
- Based on the technology type, the monoclonal antibodies segment dominated the market in 2020. Monoclonal antibodies specifically target the effected cells and helps in the better treatment. Moreover, the less toxicity and low risks of side-effects as it does not affects the normal cells is a major factor that boosted the demand for the monoclonal antibodies across the globe.
- Based on the application, the breast cancer segment is estimated to be the most opportunistic segment during the forecast period. The rapidly growing cases of breast cancer among the global women population is the primary factor behind this. According to the International Agency for Cancer Research, breast cancer has become the most diagnosed type of cancer across the globe and this alarming rise in the growth rate of breast cancer is anticipated to boost this segment.
- Based on the end user, the hospitals segment dominated the market in 2020. The rising number of hospital admissions owing to the surging growth in the number of cancer cases and deaths has boosted the growth of this growth. The rising government expenditure on the development of the healthcare infrastructure especially in the developed nations is further expected to fuel the market growth.
Segments Covered in the Report
By Technology Type
- Monoclonal Antibodies
- Cytokines & Immunomodulators
- Checkpoint Inhibitors
- Others
By Cancer Type
- Lungs Cancer
- Colorectal Cancer
- Melanoma
- Breast Cancer
- Head & Neck Cancer
- Prostate Cancer
- Others
By End User
- Hospitals
- Clinics
- Cancer Research Centers
Regional Segmentation
– North America (U.S. and Canada)
– Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
– Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
– Latin America (Brazil and Rest of Latin America)
– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Why should you invest in this report?
If you are aiming to enter the global cancer immunotherapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cancer immunotherapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1394
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Immunotherapy Market
5.1. COVID-19 Landscape: Cancer Immunotherapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Immunotherapy Market, By Technology
8.1. Cancer Immunotherapy Market, by Technology Type, 2021-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Cytokines & Immunomodulators
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Checkpoint Inhibitors
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Cancer Immunotherapy Market, By Cancer
9.1. Cancer Immunotherapy Market, by Cancer, 2021-2030
9.1.1. Lungs Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Breast Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Head & Neck Cancer
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Prostate Cancer
9.1.6.1. Market Revenue and Forecast (2019-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Cancer Immunotherapy Market, By End User
10.1. Cancer Immunotherapy Market, by End User, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Cancer Research Centers
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.1.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.2.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.3.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Cancer (2019-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)
Chapter 12. Company Profiles
12.1. Amgen, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Astrazeneca, PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bayer AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bristol-Myers Squibb Company
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eli Lily And Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. Hoffmann-La Roche, Ltd
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Johnson & Johnson
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGAA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Novartis AG
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1394
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
